100 results
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
1 Apr 21
EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors
6:55am
for enhancing operational capabilities to drive growth and Mr. Shapiro’s extensive clinical-regulatory strategy and business development experience … regulatory strategy and clinical operations across a number of anterior and posterior segment indications for Ora’s service business in ophthalmology
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
8 Nov 21
EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company’s
7:32am
Exhibit 99.1
EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company’s
Sharpened Clinical Development Strategy
SALT LAKE CITY, UT … , inherited degenerative retinal disease, Retinitis Pigmentosa. The Company’s newly revamped clinical development strategy is available in the Investors
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
27 May 21
Regulation FD Disclosure
7:01am
and bioavailability work) – IND planned for 2022
17 PP - 001: Oncology Development Strategy PP - 001 as the most potent DHODHi showed in vitro activity … , 1 vehicle) – Co - primary endpoin t includes both signs and symptoms OBG Dry Eye Development Strategy and Upcoming Catalysts
30 ALLERGIC
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
14 Sep 20
Regulation FD Disclosure
6:50am
annually in the United States 1 16 million Bacterial Conjunctivitis Primary signs are discharge and redness
TB D 9 OBG Commercialization Strategy Wound … ) – Objective is 90% gross margin Go - to - market strategy underway for in - house commercialization Customer is a small group of specialists that perform
424B3
KPRX
Kiora Pharmaceuticals Inc
21 Nov 22
Prospectus supplement
7:01am
events, conditions, and financial trends that may affect our plan of operation, business strategy, operating results, and financial position. You
8-K
EX-99.1
0pr9fqy0wnfdsm7q
16 Sep 22
Kiora Pharmaceuticals Appoints Melissa Tosca as Executive Vice President of Finance
4:30pm
8-K
EX-99.2
mwcobgr b1du7
1 Feb 21
Departure of Directors or Certain Officers
6:55am
8-K
EX-10.1
uqp0r j89
10 Jul 15
EyeGate Signs Licensing Agreement with Valeant Pharmaceuticals for EGP-437 Combination Product in Uveitis
12:00am
8-K
EX-99.1
blusdy
26 Jul 21
EyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D., as President and Chief Executive Officer
4:18pm
8-K
EX-99.1
cspu t34c8yicmpi30d
9 Nov 23
Results of Operations and Financial Condition
7:01am
8-K
0brx i8mk4f254u0hwj
26 Jul 21
EyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D., as President and Chief Executive Officer
4:18pm
424B3
xit5qoa
28 Dec 22
Prospectus supplement
4:48pm
424B3
gjxvf4
30 Apr 21
Prospectus supplement
5:01pm
424B1
7q6mkaw4h06xv
2 Jun 23
Prospectus with pricing info
5:08pm
424B1
qeoy a8s1us6
22 Jul 22
Prospectus with pricing info
6:00pm